Arrowhead Pharmaceuticals (ARWR) News Today

Capital International Investors cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 62.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 479,106 shares of the biotechnology co

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for Arrowhead Pharmaceuticals in a note issued to investors on Tuesday, July 23rd. HC Wainwright analyst P. Trucchio now expects that the biotechnol

SG Americas Securities LLC lessened its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 78.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,355 shares o

Seven Eight Capital LP grew its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 592.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 75,224 shares of the biotechnology company's stock after purch

HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday.

Ontario Teachers Pension Plan Board boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 1,239.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,883

Swiss National Bank raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 21.2% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 243,300 shares of the biotechnology company's stock after buying an additional 42,600 shares durin

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the co

Chardan Capital restated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday.

StockNews.com raised shares of Arrowhead Pharmaceuticals to a "sell" rating in a research report on Tuesday.

Susquehanna Fundamental Investments LLC purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 128,083 shares of the

Nvwm LLC acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 27,581 shares of the biotechnology company's stock, valued at approximately $7

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 67.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 327,782 shares of the biotechno

HC Wainwright reiterated a "buy" rating and issued a $60.00 price target (down from $90.00) on shares of Arrowhead Pharmaceuticals in a report on Friday.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider Tracie Oliver sold 9,394 shares of the stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total transaction of $237,480.32. Following the completion of the sale, the insider now owns 127,107 shares of the company's stock, valued at approximately $3,213,264.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a "sell" rating in a report on Tuesday.

Vanguard Group Inc. reduced its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 1.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,672,076 shares of the biotechnology compa

Global Assets Advisory LLC purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 40,242 shares of the biotechnology company's stock, valued

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 3.3%

Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and seven have issued a

Goldman Sachs Group Inc. raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 136.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,061,967 shares of the biotechnology company

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading 3.2% Higher

Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arrowhead Pharmaceuticals in a research report on Thursday.

Healthcare of Ontario Pension Plan Trust Fund grew its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 63.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,000 shares of

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.8%

Eventide Asset Management LLC purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 313,289 shares of the biotechnology compa

Avidity Partners Management LP decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 32.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 714,000 shares of the biotechnology company's stock after selling 349,897 shares

HC Wainwright reiterated a "buy" rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday.

Avoro Capital Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 100.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,130,000 shares of the biotechnology company

Sectoral Asset Management Inc. lessened its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 94.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,182 shares of the biotechnology company's stock after sel

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Research analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research report issued on Monday, June 3rd. Leerink Partnrs analyst M. Foroohar now anticipates that the bio

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 2.6%

Rafferty Asset Management LLC increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 22.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 365,087 share

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 7.3%

Eagle Asset Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 553,860 shares of the bio